Ad
related to: treatment of carbapenem resistant pseudomonas
Search results
Results from the WOW.Com Content Network
Backbone structure of a carbapenem. Carbapenems are a class of very effective antibiotic agents most commonly used for treatment of severe bacterial infections.This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections.
Carbapenem-resistant Enterobacteriaceae (CRE) have been defined as carbapenem-nonsusceptible and extended-spectrum cephalosporin-resistant Escherichia coli, Enterobacter aerogenes, Enterobacter cloacae complex, Klebsiella pneumoniae, or Klebsiella oxytoca. Some exclude ertapenem resistance from the definition.
Meropenem, sold under the brand name Merrem among others, is an intravenous carbapenem antibiotic used to treat a variety of bacterial infections. [3] Some of these include meningitis, intra-abdominal infection, pneumonia, sepsis, and anthrax.
Doripenem (Doribax, Finibax) is an antibiotic drug in the carbapenem class. It is a beta-lactam antibiotic drug able to kill Pseudomonas aeruginosa.. Doripenem can be used for bacterial infections such as: complex abdominal infections, pneumonia within the setting of a hospital, and complicated infections of the urinary tract including kidney infections with sepsis.
NDM-1 [1] is an enzyme that makes bacteria resistant to a broad range of beta-lactam antibiotics.These include the antibiotics of the carbapenem family, which are a mainstay for the treatment of antibiotic-resistant bacterial infections.
The concern is that carbapenem is often used as a drug of last resort when battling resistant bacterial strains. New slight mutations could result in infections for which healthcare professionals can do very little, if anything, to treat patients with resistant organisms. A number of mechanisms cause carbapenem resistance in the Enterobacteriaceae.
Treatment of such infections can be difficult due to multiple antibiotic resistance, [4] and in the United States, there was an increase in MDRPA (Multidrug-resistant Pseudomonas aeruginosa) resistant to ceftazidime, ciprofloxacin, and aminoglycosides, from 0.9% in 1994 to 5.6% in 2002. [5]
Eravacycline has shown broad spectrum of activity against a variety of Gram-positive and Gram-negative bacteria, including multi-drug resistant strains, such as methicillin-resistant Staphylococcus aureus and carbapenem-resistant Enterobacteriaceae. [5] It is currently being formulated as for intravenous and oral administration. [citation needed]
Ad
related to: treatment of carbapenem resistant pseudomonas